Blog

Normal deglutition requires a highly synchronized sequence of muscular contractions and sphincter relaxations to propel ingested food and liquids from the oral cavity into the stomach. The esophagus accomplishes this through primary peristalsis, a progressive wave of smooth muscle contractions, synchronized with the transient relaxation of the lower esophageal sphincter. The lower esophageal sphincter serves as a specialized high-pressure muscular zone at the gastroesophageal junction, remaining tonically contracted at rest to prevent acid reflux and relaxing upon swallowing to allow bolus entry into the gastric lumen. Achalasia is a primary esophageal motor disorder defined by two core pathophysiological features: the failure of the lower esophageal sphincter to relax completely during swallowing and the complete loss of normal progressive peristalsis throughout the smooth muscle esophagus. This loss of coordination severely impairs food transport, causing structural food stasis and progressive esophageal dilation.

Neuromuscular Pathophysiology and Ganglion Cell Loss

The underlying defect in achalasia involves the selective destruction of inhibitory postganglionic neurons within the myenteric (Auerbach's) plexus of the esophageal wall. Under normal physiological conditions, esophageal motility is regulated by a delicate balance between excitatory cholinergic neurons, which release acetylcholine to induce muscular contraction, and inhibitory non-adrenergic, non-cholinergic neurons, which release nitric oxide and vasoactive intestinal peptide to mediate smooth muscle relaxation. In individuals with achalasia, a chronic inflammatory process—often triggered by an autoimmune response, viral infection, or genetic susceptibility—leads to the localized degeneration and loss of these nitric oxide-producing inhibitory ganglion cells. Without adequate inhibitory signaling, the smooth muscle of the lower esophageal sphincter remains in a state of persistent hypertonia and cannot relax in response to a swallow. Simultaneously, the lack of coordinated inhibitory tone along the esophageal body disrupts normal peristaltic progression, resulting in uncoordinated, simultaneous contractions or complete aperistalsis.

Clinical Presentation and Progressive Dysphagia Manifestations

The clinical onset of achalasia is typically insidious, with symptoms developing gradually over several months or years before a definitive diagnosis is established. The cardinal clinical manifestation is progressive dysphagia to both solids and liquids from the outset, distinguishing it from mechanical obstructions like esophageal strictures or carcinomas, which initially affect solid foods alone. As food and fluids accumulate within the obstructed esophageal lumen, patients experience persistent regurgitation of undigested food, often occurring hours after meals or upon lying flat at night. Additional common symptoms include retrosternal chest pain caused by esophageal spasms or distension, severe heartburn unresponsive to acid suppression therapy, nocturnal coughing, and recurrent pulmonary aspiration.

Esophageal Remodeling and Secondary Complications

Chronic functional obstruction at the gastroesophageal junction leads to marked structural alteration of the esophageal body. In response to this chronic pressure load, the smooth muscle wall of the esophagus initially undergoes compensatory hypertrophy. However, as the disease advances and the neuromuscular degeneration persists, the esophageal wall stretches, thins, and loses contractility, resulting in massive dilation. This advanced structural transformation is known as megaesophagus or sigmoid esophagus, where the esophagus becomes tortuous and dilated, holding large volumes of stagnant material. Long-term stasis of decomposing food particles causes chronic mucosal irritation and inflammation (esophagitis), increasing the risk of mucosal ulceration, candidiasis, and long-term development of esophageal squamous cell carcinoma.

Diagnostic Evaluation Protocols and Manometric Classification

Accurate diagnosis of achalasia requires a combination of radiographic, endoscopic, and high-resolution physiological testing to confirm motor abnormalities and exclude mechanical obstruction. Upper gastrointestinal endoscopy is essential to visualize the esophageal lumen, evaluate mucosal integrity, and rule out pseudoachalasia caused by malignant tumors at the cardiac orifice. A barium swallow radiograph typically reveals classic structural signs: a markedly dilated esophageal body tapering smoothly to a narrow, pointed point at the gastroesophageal junction, producing the characteristic "bird's-beak" appearance, along with slow clearing of contrast material. High-resolution esophageal manometry serves as the gold-standard diagnostic tool, measuring precise pressure profiles along the esophagus. According to the Chicago Classification, achalasia is categorized into three distinct manometric subtypes based on esophageal body pressure patterns: Type I (classic achalasia with complete aperistalsis and no esophageal compression), Type II (achalasia with pan-esophageal pressurization), and Type III (spastic achalasia characterized by high-amplitude, lumen-obliterating spastic contractions).

Therapeutic Management and Interventional Strategies

Because current medical science cannot restore lost myenteric ganglion cells, treatment for achalasia focuses entirely on reducing lower esophageal sphincter resting pressure to facilitate gravity-assisted passage of food into the stomach. Pharmacological options, such as calcium channel blockers or nitrates, offer temporary smooth muscle relaxation but are limited by modest efficacy and systemic side effects, serving primarily as bridge therapies for high-risk patients. Localized endoscopic injection of botulinum toxin into the sphincter muscle blocks acetylcholine release, providing short-term relief, though symptoms frequently recur within months. Definitive interventions aim to mechanically disrupt the hypertensive sphincter muscle. Pneumatic balloon dilation uses graded air pressure to tear the muscular fibers of the sphincter, offering durable relief but carrying a small risk of esophageal perforation. Surgical approaches, including laparoscopic Heller myotomy (often combined with a partial fundoplication to prevent secondary acid reflux) and Peroral Endoscopic Myotomy (POEM), cut the circular muscle fibers of the lower esophageal sphincter, providing long-term improvement in swallowing function.

Conclusion

Achalasia is a chronic, progressive esophageal motility disorder caused by the loss of inhibitory myenteric neurons, leading to lower esophageal sphincter hypertonia and complete esophageal aperistalsis. Understanding how this neuromuscular failure induces structural food stasis, progressive luminal dilation, and severe dysphagia clarifies the functional impact experienced by affected individuals. Utilizing high-resolution manometry, barium radiography, and upper endoscopy allows clinical teams to establish an accurate diagnosis, classify disease subtypes, and rule out structural malignancies. Through targeted therapeutic interventionssuch as pneumatic dilation, Heller myotomy, or peroral endoscopic myotomy, clinicians can successfully lower sphincter resistance, restore effective foodtransit into the stomach, and significantly improve overall quality of life.